Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke

Summary

Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production. Immune thrombocytopenia may increase the risk of cerebral infarction and represents a relatively uncommon etiology of acute ischemic stroke. This disease is associated with high disability and mortality rates, poses significant therapeutic challenges, and constitutes a serious threat to human health. Therefore, research on the diagnosis, treatment, and prognosis of ITP combined with acute ischemic stroke is of great significance for improving patients' quality of life and survival outcomes. However, most current hematologic cohort studies are based on single-center or limited multicenter sample sizes, lacking comprehensive and large-scale prospective cohort studies. Our center plans to conduct a large-sample, combined retrospective and prospective longitudinal cohort study. This study will register patients' basic information and diagnosis, follow up with patients through questionnaires, telephone calls, video consultations, online platforms, and in-person visits to record treatment and comorbidity data, collect prognostic information, and retrieve hospitalization and outpatient costs through medical record systems. The study aims to provide comprehensive data on the incidence, treatment, prognosis, and healthcare costs of ITP patients with acute ischemic stroke in China.

Conditions

• Immune Thrombocytopenia (ITP)
• Acute Ischemic Stroke

Sponsors & Collaborators

• Jiangsu province hospital of TCM

  collaborator UNKNOWN

• Army Medical University, China

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• Ningbo University Affiliated People's Hospital

  collaborator UNKNOWN

• West China Hospital

  collaborator OTHER

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• The Second Hospital Of Hebe Medical University

  collaborator UNKNOWN

• Kunming Medical University Second Affiliated Hospital

  collaborator UNKNOWN

• Shanghai Zhongshan Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Huazhong Science & Technology Shanxi Baiqiu En Hospital

  collaborator UNKNOWN

• NORTHERN JIANGSU PEOPLE'S HOSPITAL 1900

  collaborator UNKNOWN

• Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology

  collaborator UNKNOWN

• Xuzhou Medical University Affiliated Hospital of Huaian

  collaborator UNKNOWN

• Affiliated Hospital of Fujian Medical University, Xiehe Branch

  collaborator UNKNOWN

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• First Affiliated Hospital of Guangxi Medical University

  collaborator OTHER

• Xiangya Third Hospital of Central South University

  collaborator UNKNOWN

• Xiangya Second Hospital of Central South University

  collaborator UNKNOWN

• Xiangya Hospital of Central South University

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Southern Medical University - Southern Hospital

  collaborator UNKNOWN

• The Second Hospital of Hebei Medical University

  collaborator OTHER

• The First Hospital Affiliated to University of Science and Technology of China

  collaborator UNKNOWN

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• North China University of Science and Technology

  collaborator OTHER

• Peking University People's Hospital

  lead OTHER

Principal Investigators

• Xiao-Hui Zhang, MD · eking University Institute of Hematology, Peking University People's Hospital

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-07-10

Primary Completion

2035-12-31

Completion

2036-12-31